Genetic Technologies Limited · ASX:GTG
Genetic Technologies — Corporate Update (July 2022)
30 slides from Genetic Technologies's corporate update, Aug 1, 2022
Slide 1: GeneType Presentation Business Update
For personal use only GeneType Presentation Business Update July 31, 2022 Authorised by the Board of Directors of Genetic Technologies Limited ASX: GTG NASDAQ: GENE
Slide 2: Notice: Forward looking statements
For personal use only Notice: Forward looking statements The purpose of the presentation is to provide an update of the business of Genetic Technologies Limited (the Company) ACN: 009 212 328 (ASX:GTG; NASDAQ:GENE). These slides have been prepared as a presentation aid only and the information they
Slide 3: Our Overview
Our Overview For personal use only Vision and World Leading Portfolio Focus Areas and Market Opportunity Unlocking personalised preventative health Seizing a Multi-billion dollar opportunity Markets & Global Presence Pathways to Market Expansion to over 40 countries with a multi brand strategy Brand
Slide 4: Genetype Vision
For personal use only Genetype Vision 4
Slide 5: Unlocking personalised preventative health
Unlocking personalised preventative For personal use only health Our Mission Transform the conversation from a one-size-fits-all model to personalised, predictive health assessment. Where each person has the information, they need to manage their health according to their own risk. Empowering physic
Slide 6: World leading portfolio
World leading portfolio For personal use only Most comprehensive portfolio for humans and animal health. • Patented GeneType Multi Risk Test • Non-Invasive Prenatal Testing (NIPT) • Carrier screen testing • Pharmacogenomics • Oncogenetic diseases • Pet care Revenues anchored by our 3 brands to seize
Slide 7: Patented integrated risk testing for a range of serious conditions
Patented integrated risk For personal use only testing for a range of serious conditions. Genetype tests integrate individual’s familial, clinical and genetic information into actionable clinical insights. Combining genetic and clinical risk models with cutting-edge research, we’re leading a persona
Slide 8: Global Overview
Global Overview For personal use only 57 40 27 Employees Countries Patents Granted globally (9 Pending) 14 51 12 Test Categories Tests Partner Laboratories 8
Slide 9: Delivering Revenue and Growth June Qtr FY22
Delivering Revenue and Growth June Qtr FY22 For personal use only Cash Receipts (A$'000) $6,789 REVENUE CASH BALANCE AUD $2.01m AUD $11.7m* half-year ending December 31, 2021 $2,013 GROSS MARGIN GROSS MARGIN $68 Q4 FY21 Q4 FY22 $89 YTD Jun FY21 YTD Jun FY22# AUD $1.0m 51% Strategic & Operational Hig
Slide 10: Commercialisation of the geneType suite of multi-risk tests
For personal use only Commercialisation of the geneType suite of multi-risk tests 6 EasyDNA Growth: New Test. New Channels. New Markets. Our Demonstrate clinical validity & clinical utility of geneType tests Focus Bolster commercial bias to our OPEX to drive revenues Areas HR, Talent & capability In
Slide 11: Market Size and Opportunity
Market Size and Opportunity Estimated Global Revenue growth is USD$2.8B in to 2025 For personal use only CAGR 16.3% Predictive Genomics1 Growth $1.3B Direct to Consumer2 CAGR 18.1% Growth $1.4B 2.01 2025 0.76 2.60 2020 1.22 USD ($B) USD ($B’m) 1. Newsire - Predictive Genetics Market Research Report
Slide 12: Marketing Performance (June Qtr)
Marketing Performance (June Qtr) For personal use only Digital Brand Performance 459,456 1,014 BRAND IMPRESSIONS CLICKS: ADS + SOCIAL 975 27,197 SOCIAL MEDIA ENGAGEMENTS WEBSITE VISITS Lead Generation 348 133 44 152 CONTACT FORM HCP PARTNERSHIP NEWSLETTER ‘REGISTER INTEREST’ SUBMISSIONS FORM SUBMISS
Slide 13: Marketing LinkedIn and socials – Genetype
Marketing LinkedIn and socials – Genetype For personal use only LinkedIn Siles LinkedIn AffinityDNA LinkedIn EasyDNA Market LinkedIn Erika PMWC Announcement Expansion 13
Slide 14: Growth strategy for EasyDNA
Growth strategy for EasyDNA For personal use only PHASE 1 PHASE 2 Brand Re-Ignition Revenue and Growth Focus [insert revenue structure and agreement types] [insert revenue structure and agreement types] Brand Refresh Website Refresh Product list Improved Lead Gen New Sales Channels Product list Mult
Slide 15: Marketing LinkedIn and socials - EasyDNA
Marketing LinkedIn and socials - EasyDNA For personal use only 15 15
Slide 16: GeneType Website – ALL tests - LIVE
GeneType Website – ALL tests - LIVE For personal use only 16
Slide 17: Pathways to Market
Pathways to Market For personal use only Direct to Consumer Consumer initiated Medical Business to Testing (DTC) testing (CIT) Business (B2B) with no medical supervision with medical supervision Revenue Leveraging the EasyDNA Brand and Platform Building consumer Awareness of serious disease test Hea
Slide 18: Pathways to Market: Executing a multi-brand strategy
Pathways to Market Executing a multi-brand strategy For personal use only 1 Direct to consumer [insert revenue structure Ancestryand agreement Animal types] Paternity Product list Health & Wellbeing Drug testing Relationship Pharmacogenetics Covid- Antigen Tests* Consumer-initiated testing 2 ± teleh
Slide 19: Our Innovation – Multi-Risk Test
Our Innovation – Multi- Risk Test A companion diagnostic PRS to help identify risk of serious disease for up to 70% of Mortalities For personal use only and Morbidities GeneType Multi-test to include >70% of mortality & Diseases Areas morbidity Oncology Cardiovascular Breast Cancer Atrial Fibrillati
Slide 20: Divisions of Operations
Divisions of Operations For personal use only NEW Existing divisions Universal collection Pharmoco- test kit to support Oncology Genetics & Taliaz Emerging divisions BC, CRC, PC, Companion Multi Test Launch Melanoma diagnostics Germline testing CVD BRCA, Lynch (Heart Disease) Syndrome and IHD, AF So
Slide 21: Snapshot and Achievements last months
Snapshot and Achievements last 12 months For personal use only GeneType commercialization EasyDNA integration activities Reimbursement activation Phase 1 commercial release of the geneType Multi-Risk test Acquisition of EasyDNA completed Independently developed Budget Impact Model (BIM) in US
Slide 22: Summary
For personal use only Summary 23
Slide 23: Thank you
For personal use only Thank you Investor Relations Justin Foord Market Eye www.linkedin.com/company/genetype-limited M: +61 402 600 691 E: justin.foord@marketeye.com.au www.genetype.com 24
Slide 24: Appendices
For personal use only Appendices 25
Slide 25: Corporate Overview
Corporate Overview For personal use only Top 50 share registry breakdown BNY Mellon Board & Management Other Dual Listed on the ASX and Nasdaq Financial Information Share price (AUD) as at 27 July 2022 0.4c Other, 25% ADR price (USD) as at 27 July 2022 $1.47 Ord Shares on Issue (M) 9,234 ASX 52-week
Slide 26: Financial Overview
Financial Overview For personal use only • Net cash inflow of A$197k in Q4 FY’22 (compared to Q3 FY’22 outflow of: A$2.1 million) as we continue to grow EasyDNA and Affinity DNA brand sales and develop and commercialize our geneType tests A$’000 31-Mar-22 30-Jun-22 Change • Cash reserves of A$11.7 m
Slide 27: Board and Management
Board and Management: Sales and Scientific expertise leading GTG For personal use only Mr. Peter Rubinstein Dr. Lindsay Wakefield Mr Nick Burrows BEc, LLB MBBS B.Com, FAICD, FCA, Chairman - Non – Executive Non – Executive Director FGIA, FTIA, F Fin Director Non – Executive Director Dr. Jerzy “George
Slide 28: Strong Scientific Leadership: Advisory Board
Strong Scientific Leadership: Advisory Board For personal use only Professor Jon Emery Professor Finlay Macrae AO Ora K. Gordon, M.D. A.Prof Ron Dick MBBCh MA DPhil FRACGP MRCGP MBBS, MD, FRACP, FRCP, AGAF MWGO is MD, MS, FACMG MBBS, FRACP, FCSANZ, Research & Education Lead, Primary Care Principal F
Slide 29: Our Intellectual Property
Our Intellectual Property For personal use only 8 Patents granted in the US 9 Patent families pending • Patent No: US 11,257,569, Methods of assessing risk of developing a severe response to Coronavirus infection • Methods for breast cancer risk assessment • Patent 11,031,098, Computer systems and m
Slide 30: Defined Terms
Defined Terms For personal use only Common Complex Diseases (CCP) – A complex disease is caused by the interaction of multiple genes and environmental factors. Complex diseases are also called multifactorial. Examples of common complex diseases include cancer and heart disease. Polygenic risk score